Donor-derived cell-free DNA in chronic lung allograft dysfunction phenotypes: a pilot study
Evidence level: human pilot; abstract-only
In 20 CLAD patients, donor-derived cell-free DNA was elevated in 47 percent of stable samples and 71 percent of established CLAD samples, with high variability and no BOS versus RAS difference.
As of . Primary source: Publisher record via DOI.
Summary
This proof-of-concept study measured plasma donor-derived cell-free DNA (dd-cfDNA) in 20 CLAD patients (11 BOS, 9 RAS) at three time points free of infection or acute rejection: stable, preclinical CLAD and established CLAD (60 samples). Elevated levels were found in 47 percent of stable samples, 66 percent of preclinical CLAD and 71 percent of CLAD samples, indicating ongoing allograft injury, but levels showed high intra- and interpatient variability and did not differ significantly between BOS and RAS (p=0.25). The authors conclude further investigation is warranted.
Details
- doi
- 10.3389/frtra.2024.1513101
- pmid
- 39764156
- authors
- Beeckmans H, Pagliazzi A, Kerckhof P, Hofkens R, Debackere F, Zajacova A, Bos S, Vanaudenaerde BM, de Loor H, Naesens M, Vos R
- journal
- Frontiers in Transplantation
- year
- 2024
- volume
- 3
Sources and links
- Publisher record via DOI (primary)
- PubMed 39764156
Related
Links from this record
- evidence for: Donor-derived cell-free DNA
- compares: Bronchiolitis obliterans syndrome (BOS)
- compares: Restrictive allograft syndrome (RAS)
- authors affiliated with: KU Leuven BREATHE (Laboratory of Respiratory Diseases and Thoracic Surgery)
- coauthor: Robin Vos
- coauthor: Bart Vanaudenaerde
Linked from (derived)
- author: Bart Vanaudenaerde
- author: Robin Vos
- evidence: CLAD is recognised late and no biomarker is validated for early warning
Known gaps in this record
- full text not read (abstract only)
- funding statement and grant numbers
- validation in a larger cohort
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.